Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: A randomized controlled trial

R. M. Hackman, Peter J Havel, H. J. Schwartz, John C Rutledge, M. R. Watnik, E. M. Noceti, S. J. Stohs, J. S. Stern, Carl L Keen

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Objective: To determine the safety and efficacy of a dietary supplement with a low dose of ephedra and caffeine in overweight/obese premenopausal female subjects. Design: A 9-month, double-blind, randomized control study compared the efficacy and safety of a dietary supplement with ephedra and caffeine to a control supplement. Subjects: Sixty-one healthy, premenopausal women with body mass index (BMI) from 27 to 39 kg/m2 were randomly assigned and received a dietary supplement (40 mg/day ephedra alkaloids, 100 mg/day caffeine, high potency mixture of vitamins, minerals, omega-3 fatty acids) or a control supplement for 9 months. Measurements: Efficacy: changes in body weight, body composition, lipids, insulin, leptin, adiponectin, ghrelin, and self-reports of physical activity, diet and quality of life indices. Safety: blood pressure, heart rate, electrocardiograms, urinalysis, blood histology, serum chemistry measures and self-reported symptoms. Results: Forty-one women completed the study. The treatment group lost significantly more body weight (-7.18 kg) and body fat (-5.33 kg) than the control group (-2.25 and -0.99 kg, respectively), and showed significant declines in heart rate, serum cholesterol, triglycerides, cholesterol to high-density lipoprotein ratio, glucose, fasting insulin, and leptin. Blood pressure, electrocardiograms, other clinical chemistry measures, blood histology, urinalysis, and self-reported physical activity were similar in the groups. Minor symptoms included dry mouth, insomnia, nervousness and palpitations. The treatment group reported more energy and decreased appetite compared to controls and scored higher on a quality of life domain assessing vitality. Conclusion: A dietary supplement containing a low potency ephedra/caffeine mixture appeared safe and effective in causing loss of weight and body fat, and improving several metabolic parameters, including insulin sensitivity and lipid profiles when tested under physician supervision. Such supplements could be a useful tool to assist with weight loss.

Original languageEnglish (US)
Pages (from-to)1545-1556
Number of pages12
JournalInternational Journal of Obesity
Volume30
Issue number10
DOIs
StatePublished - Oct 14 2006

Fingerprint

Ephedra
caffeine
Dietary Supplements
Caffeine
dietary supplements
Weight Loss
risk factors
weight loss
Randomized Controlled Trials
Urinalysis
urinalysis
electrocardiography
Leptin
leptin
quality of life
Safety
physical activity
histology
body fat
signs and symptoms (animals and humans)

Keywords

  • (MeSH) ephedra
  • Dietary supplement
  • Insulin
  • Leptin
  • Lipids
  • Weight loss

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism

Cite this

Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women : A randomized controlled trial. / Hackman, R. M.; Havel, Peter J; Schwartz, H. J.; Rutledge, John C; Watnik, M. R.; Noceti, E. M.; Stohs, S. J.; Stern, J. S.; Keen, Carl L.

In: International Journal of Obesity, Vol. 30, No. 10, 14.10.2006, p. 1545-1556.

Research output: Contribution to journalArticle

Hackman, R. M. ; Havel, Peter J ; Schwartz, H. J. ; Rutledge, John C ; Watnik, M. R. ; Noceti, E. M. ; Stohs, S. J. ; Stern, J. S. ; Keen, Carl L. / Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women : A randomized controlled trial. In: International Journal of Obesity. 2006 ; Vol. 30, No. 10. pp. 1545-1556.
@article{28a44552259e45d0aed5833067e5bb36,
title = "Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: A randomized controlled trial",
abstract = "Objective: To determine the safety and efficacy of a dietary supplement with a low dose of ephedra and caffeine in overweight/obese premenopausal female subjects. Design: A 9-month, double-blind, randomized control study compared the efficacy and safety of a dietary supplement with ephedra and caffeine to a control supplement. Subjects: Sixty-one healthy, premenopausal women with body mass index (BMI) from 27 to 39 kg/m2 were randomly assigned and received a dietary supplement (40 mg/day ephedra alkaloids, 100 mg/day caffeine, high potency mixture of vitamins, minerals, omega-3 fatty acids) or a control supplement for 9 months. Measurements: Efficacy: changes in body weight, body composition, lipids, insulin, leptin, adiponectin, ghrelin, and self-reports of physical activity, diet and quality of life indices. Safety: blood pressure, heart rate, electrocardiograms, urinalysis, blood histology, serum chemistry measures and self-reported symptoms. Results: Forty-one women completed the study. The treatment group lost significantly more body weight (-7.18 kg) and body fat (-5.33 kg) than the control group (-2.25 and -0.99 kg, respectively), and showed significant declines in heart rate, serum cholesterol, triglycerides, cholesterol to high-density lipoprotein ratio, glucose, fasting insulin, and leptin. Blood pressure, electrocardiograms, other clinical chemistry measures, blood histology, urinalysis, and self-reported physical activity were similar in the groups. Minor symptoms included dry mouth, insomnia, nervousness and palpitations. The treatment group reported more energy and decreased appetite compared to controls and scored higher on a quality of life domain assessing vitality. Conclusion: A dietary supplement containing a low potency ephedra/caffeine mixture appeared safe and effective in causing loss of weight and body fat, and improving several metabolic parameters, including insulin sensitivity and lipid profiles when tested under physician supervision. Such supplements could be a useful tool to assist with weight loss.",
keywords = "(MeSH) ephedra, Dietary supplement, Insulin, Leptin, Lipids, Weight loss",
author = "Hackman, {R. M.} and Havel, {Peter J} and Schwartz, {H. J.} and Rutledge, {John C} and Watnik, {M. R.} and Noceti, {E. M.} and Stohs, {S. J.} and Stern, {J. S.} and Keen, {Carl L}",
year = "2006",
month = "10",
day = "14",
doi = "10.1038/sj.ijo.0803283",
language = "English (US)",
volume = "30",
pages = "1545--1556",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women

T2 - A randomized controlled trial

AU - Hackman, R. M.

AU - Havel, Peter J

AU - Schwartz, H. J.

AU - Rutledge, John C

AU - Watnik, M. R.

AU - Noceti, E. M.

AU - Stohs, S. J.

AU - Stern, J. S.

AU - Keen, Carl L

PY - 2006/10/14

Y1 - 2006/10/14

N2 - Objective: To determine the safety and efficacy of a dietary supplement with a low dose of ephedra and caffeine in overweight/obese premenopausal female subjects. Design: A 9-month, double-blind, randomized control study compared the efficacy and safety of a dietary supplement with ephedra and caffeine to a control supplement. Subjects: Sixty-one healthy, premenopausal women with body mass index (BMI) from 27 to 39 kg/m2 were randomly assigned and received a dietary supplement (40 mg/day ephedra alkaloids, 100 mg/day caffeine, high potency mixture of vitamins, minerals, omega-3 fatty acids) or a control supplement for 9 months. Measurements: Efficacy: changes in body weight, body composition, lipids, insulin, leptin, adiponectin, ghrelin, and self-reports of physical activity, diet and quality of life indices. Safety: blood pressure, heart rate, electrocardiograms, urinalysis, blood histology, serum chemistry measures and self-reported symptoms. Results: Forty-one women completed the study. The treatment group lost significantly more body weight (-7.18 kg) and body fat (-5.33 kg) than the control group (-2.25 and -0.99 kg, respectively), and showed significant declines in heart rate, serum cholesterol, triglycerides, cholesterol to high-density lipoprotein ratio, glucose, fasting insulin, and leptin. Blood pressure, electrocardiograms, other clinical chemistry measures, blood histology, urinalysis, and self-reported physical activity were similar in the groups. Minor symptoms included dry mouth, insomnia, nervousness and palpitations. The treatment group reported more energy and decreased appetite compared to controls and scored higher on a quality of life domain assessing vitality. Conclusion: A dietary supplement containing a low potency ephedra/caffeine mixture appeared safe and effective in causing loss of weight and body fat, and improving several metabolic parameters, including insulin sensitivity and lipid profiles when tested under physician supervision. Such supplements could be a useful tool to assist with weight loss.

AB - Objective: To determine the safety and efficacy of a dietary supplement with a low dose of ephedra and caffeine in overweight/obese premenopausal female subjects. Design: A 9-month, double-blind, randomized control study compared the efficacy and safety of a dietary supplement with ephedra and caffeine to a control supplement. Subjects: Sixty-one healthy, premenopausal women with body mass index (BMI) from 27 to 39 kg/m2 were randomly assigned and received a dietary supplement (40 mg/day ephedra alkaloids, 100 mg/day caffeine, high potency mixture of vitamins, minerals, omega-3 fatty acids) or a control supplement for 9 months. Measurements: Efficacy: changes in body weight, body composition, lipids, insulin, leptin, adiponectin, ghrelin, and self-reports of physical activity, diet and quality of life indices. Safety: blood pressure, heart rate, electrocardiograms, urinalysis, blood histology, serum chemistry measures and self-reported symptoms. Results: Forty-one women completed the study. The treatment group lost significantly more body weight (-7.18 kg) and body fat (-5.33 kg) than the control group (-2.25 and -0.99 kg, respectively), and showed significant declines in heart rate, serum cholesterol, triglycerides, cholesterol to high-density lipoprotein ratio, glucose, fasting insulin, and leptin. Blood pressure, electrocardiograms, other clinical chemistry measures, blood histology, urinalysis, and self-reported physical activity were similar in the groups. Minor symptoms included dry mouth, insomnia, nervousness and palpitations. The treatment group reported more energy and decreased appetite compared to controls and scored higher on a quality of life domain assessing vitality. Conclusion: A dietary supplement containing a low potency ephedra/caffeine mixture appeared safe and effective in causing loss of weight and body fat, and improving several metabolic parameters, including insulin sensitivity and lipid profiles when tested under physician supervision. Such supplements could be a useful tool to assist with weight loss.

KW - (MeSH) ephedra

KW - Dietary supplement

KW - Insulin

KW - Leptin

KW - Lipids

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=33749121586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749121586&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0803283

DO - 10.1038/sj.ijo.0803283

M3 - Article

C2 - 16552410

AN - SCOPUS:33749121586

VL - 30

SP - 1545

EP - 1556

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 10

ER -